Anonymous
Guest
Anonymous
Guest
Saw this on another thread and thought it was worthy of its OWN thread. Hmmmmmm.....
Based on this Bloomberg article below.... I'm gonna say YES... The FDA is aware!!! And this is ONLY in FOUR MONTHS (May-Oct)!!! And it's only the ones that were REPORTED!!!
I'm happy to say I'M A MERCK REP!!! And I know the Vertex reps are NOT reporting the rashes to the FDA when offices tell them about it.... But guess what??? I AM!!!!! There have been 2 cases of SJS in my territory due to Incivek and the rep DID NOT report them..... Well no worries!!! Cause I did!! YOU'RE WELCOME VERTEX!!!
VERTEX FALLS AS FDA DATABASE SHOWS INCIVEK ADVERSE EVENTS: Favus
By Sasha Damouni and Clyde Eltzroth
Oct. 26 (Bloomberg) – Vertex down as much as 6.4% after Incivek showed 417 related adverse events (May 23-Oct. 17), entered into FDA Adverse Events Reporting System (AERS), Favus analyst Elliot Favus said in a note after contacting the FDA.
• Toxicity profile of Incivek worse than Favus expected; total of 20 cases of Stevens-
Johnson syndrome (3) and drug rash with eosinophilia and systemic systems (17) have
been reported since Incivek rollout: Favus
• Regulators, investors will begin following ration of SJS/DRESS cases, since the ratio may
become "intolerable" to doctors, patients, FDA: Favus
• SJS, DRESS normally extremely rare, life-threatening, drug-induced skin reactions with
multi-organ system failure: Favus
• VRTX up 11% in last 12 months vs S&P 300 Health Care Index up 9.3%
• VRTX 13 buys, 8 holds, 3 sells, avg. PT $57: Bloomberg data
Based on this Bloomberg article below.... I'm gonna say YES... The FDA is aware!!! And this is ONLY in FOUR MONTHS (May-Oct)!!! And it's only the ones that were REPORTED!!!
I'm happy to say I'M A MERCK REP!!! And I know the Vertex reps are NOT reporting the rashes to the FDA when offices tell them about it.... But guess what??? I AM!!!!! There have been 2 cases of SJS in my territory due to Incivek and the rep DID NOT report them..... Well no worries!!! Cause I did!! YOU'RE WELCOME VERTEX!!!
VERTEX FALLS AS FDA DATABASE SHOWS INCIVEK ADVERSE EVENTS: Favus
By Sasha Damouni and Clyde Eltzroth
Oct. 26 (Bloomberg) – Vertex down as much as 6.4% after Incivek showed 417 related adverse events (May 23-Oct. 17), entered into FDA Adverse Events Reporting System (AERS), Favus analyst Elliot Favus said in a note after contacting the FDA.
• Toxicity profile of Incivek worse than Favus expected; total of 20 cases of Stevens-
Johnson syndrome (3) and drug rash with eosinophilia and systemic systems (17) have
been reported since Incivek rollout: Favus
• Regulators, investors will begin following ration of SJS/DRESS cases, since the ratio may
become "intolerable" to doctors, patients, FDA: Favus
• SJS, DRESS normally extremely rare, life-threatening, drug-induced skin reactions with
multi-organ system failure: Favus
• VRTX up 11% in last 12 months vs S&P 300 Health Care Index up 9.3%
• VRTX 13 buys, 8 holds, 3 sells, avg. PT $57: Bloomberg data